Earnings-season performance will be a decisive factor for the "virx stock forecast" trajectory. Analysts expect EPS improvements fueled by partnership agreements in niche biotech markets. Viracta Therapeutics, Inc.finds support from accumulated volume at $0.158 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "ve... The RBC view may turn out to be conservative when it comes to VIRX. The stock's Strong Buy consensus rating is based on unanimous reviews from 4 analysts, and the average price target of $16.75 implies a sky-high upside potential of 1,245% from the current share price of $1.25. (See VIRX stock forecast ) Medium-term "virx stock forecast" scenarios anticipate a 15% rise if R&D milestones are achieved. Technical traders recommend monitoring Bollinger Bands for breakout signals.